We examined inflammation-based prognostic scores in 121 patients with advanced urothelial carcinoma (UC) and 65 patients with metastatic renal cell carcinoma who received PD-1 antibody. The combination of several inflammation-based prognostic scores may be a potential biomarker for estimating prognosis in patients with those carcinomas treated by PD-1 antibody.
A PCR-based assay and DNA microarray showed Microsatellite instability (MSI)-high and the immunohistochemistry of mismatch repair genes showed decreased expression of MSH2 and MSH6 protein in both the primary bladder and the metastatic tumor. Whole-exome sequencing revealed somatic MSH2 mutation c.1351C>T (p.Gln451Ter) in the primary bladder and metastatic tumors, while this germline mutation was not detected. The somatic MSH2 (c.1351C>T) mutation is associated with MMR-deficiency and MSI-high which enabled a long-term complete response to anti-PD-1 antibody in a metastatic UC of the bladder.
